论文部分内容阅读
第65届美国肝病研究学会(AASLD)年会上,中国首个丙肝病毒和人类基因多态性流行病学调查(CCgenos)关于中国丙肝患者治疗情况的子研究的第一年研究结果首次公布。512名患者中逾1/3的丙肝患者没有在确诊后第一年接受抗病毒治疗。专家指出,丙肝危害不亚于乙肝,慢性丙肝也是肝硬化和肝癌的重要诱因。与会专家介绍,除干扰素禁忌症患者外,开始治疗的患者中大概有1/10不能耐受干扰素治疗,
At the 65th Annual Meeting of the American Society of Hepatology Research (AASLD), the first year of a first-year study of China’s first hepatitis C virus and human genetic polymorphism epidemiology survey (CCgenos) on the treatment of hepatitis C patients in China was first published. Over one-third of 512 patients with hepatitis C did not receive antiviral therapy in the first year after diagnosis. Experts point out that hepatitis C harm no less than hepatitis B, chronic hepatitis C is also an important cause of cirrhosis and liver cancer. Participating experts, in addition to interferon contraindications patients, the beginning of treatment of patients about 1/10 can not tolerate interferon treatment,